BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31429359)

  • 1. The impact of proton LET/RBE modeling and robustness analysis on base-of-skull and pediatric craniopharyngioma proton plans relative to VMAT.
    Gutierrez A; Rompokos V; Li K; Gillies C; D'Souza D; Solda F; Fersht N; Chang YC; Royle G; Amos RA; Underwood T
    Acta Oncol; 2019 Dec; 58(12):1765-1774. PubMed ID: 31429359
    [No Abstract]   [Full Text] [Related]  

  • 2. Reoptimization of Intensity Modulated Proton Therapy Plans Based on Linear Energy Transfer.
    Unkelbach J; Botas P; Giantsoudi D; Gorissen BL; Paganetti H
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1097-1106. PubMed ID: 27869082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric comparison of distal esophageal carcinoma plans for patients treated with small-spot intensity-modulated proton versus volumetric-modulated arc therapies.
    Liu C; Bhangoo RS; Sio TT; Yu NY; Shan J; Chiang JS; Ding JX; Rule WG; Korte S; Lara P; Ding X; Bues M; Hu Y; DeWees T; Ashman JB; Liu W
    J Appl Clin Med Phys; 2019 Jul; 20(7):15-27. PubMed ID: 31112371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer.
    Seco J; Gu G; Marcelos T; Kooy H; Willers H
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):188-94. PubMed ID: 23920395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study.
    Liu G; Li X; Qin A; Zheng W; Yan D; Zhang S; Stevens C; Kabolizadeh P; Ding X
    Radiat Oncol; 2020 Jan; 15(1):21. PubMed ID: 32000817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower doses to hippocampi and other brain structures for skull-base meningiomas with intensity modulated proton therapy compared to photon therapy.
    Florijn MA; Sharfo AWM; Wiggenraad RGJ; van Santvoort JPC; Petoukhova AL; Hoogeman MS; Mast ME; Dirkx MLP
    Radiother Oncol; 2020 Jan; 142():147-153. PubMed ID: 31522879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers.
    Liu W; Mohan R; Park P; Liu Z; Li H; Li X; Li Y; Wu R; Sahoo N; Dong L; Zhu XR; Grosshans DR
    Pract Radiat Oncol; 2014; 4(6):384-91. PubMed ID: 25407859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Training and validation of a knowledge-based dose-volume histogram predictive model in the optimisation of intensity-modulated proton and volumetric modulated arc photon plans for pleural mesothelioma patients.
    Franceschini D; Cozzi L; Fogliata A; Marini B; Di Cristina L; Dominici L; Spoto R; Franzese C; Navarria P; Comito T; Reggiori G; Tomatis S; Scorsetti M
    Radiat Oncol; 2022 Aug; 17(1):150. PubMed ID: 36028862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the benefits and risks of proton therapy in pediatric craniopharyngioma.
    Beltran C; Roca M; Merchant TE
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e281-7. PubMed ID: 21570209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases.
    Tran A; Zhang J; Woods K; Yu V; Nguyen D; Gustafson G; Rosen L; Sheng K
    Radiat Oncol; 2017 Jan; 12(1):10. PubMed ID: 28077128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas.
    Boehling NS; Grosshans DR; Bluett JB; Palmer MT; Song X; Amos RA; Sahoo N; Meyer JJ; Mahajan A; Woo SY
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):643-52. PubMed ID: 21277111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes.
    Grosshans DR; Zhu XR; Melancon A; Allen PK; Poenisch F; Palmer M; McAleer MF; McGovern SL; Gillin M; DeMonte F; Chang EL; Brown PD; Mahajan A
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):540-6. PubMed ID: 25304948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difference in LET-based biological doses between IMPT optimization techniques: Robust and PTV-based optimizations.
    Hirayama S; Matsuura T; Yasuda K; Takao S; Fujii T; Miyamoto N; Umegaki K; Shimizu S
    J Appl Clin Med Phys; 2020 Apr; 21(4):42-50. PubMed ID: 32150329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust intensity-modulated proton therapy to reduce high linear energy transfer in organs at risk.
    An Y; Shan J; Patel SH; Wong W; Schild SE; Ding X; Bues M; Liu W
    Med Phys; 2017 Dec; 44(12):6138-6147. PubMed ID: 28976574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization.
    Liu W; Frank SJ; Li X; Li Y; Zhu RX; Mohan R
    Med Phys; 2013 Feb; 40(2):021709. PubMed ID: 23387732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric evaluation of photons versus protons in postmastectomy planning for ultrahypofractionated breast radiotherapy.
    Oonsiri P; Nantavithya C; Lertbutsayanukul C; Sarsitthithum T; Vimolnoch M; Tawonwong T; Saksornchai K
    Radiat Oncol; 2022 Jan; 17(1):20. PubMed ID: 35093111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of grid size on uniform scanning and IMPT plans in XiO treatment planning system for brain cancer.
    Rana S; Zheng Y
    J Appl Clin Med Phys; 2015 Sep; 16(5):447–456. PubMed ID: 26699310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy.
    Underwood T; Giantsoudi D; Moteabbed M; Zietman A; Efstathiou J; Paganetti H; Lu HM
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):454-464. PubMed ID: 27084660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can differences in linear energy transfer and thus relative biological effectiveness compromise the dosimetric advantage of intensity-modulated proton therapy as compared to passively scattered proton therapy?
    Giantsoudi D; Adams J; MacDonald S; Paganetti H
    Acta Oncol; 2018 Sep; 57(9):1259-1264. PubMed ID: 29726722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linear energy transfer-guided optimization in intensity modulated proton therapy: feasibility study and clinical potential.
    Giantsoudi D; Grassberger C; Craft D; Niemierko A; Trofimov A; Paganetti H
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):216-22. PubMed ID: 23790771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.